This HTML5 document contains 74 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/drugbank/
n19http://linked.opendata.cz/resource/mesh/concept/
n27http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n28http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/national-drug-code-directory/
n24http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n16http://www.rxlist.com/cgi/generic/
n23http://linked.opendata.cz/resource/drugbank/patent/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n25http://linked.opendata.cz/resource/drugbank/medicinal-product/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/pharmgkb/
n18http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n26http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n17http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/pubchem-compound/
n7http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/pubchem-substance/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01610
rdf:type
n3:Drug
n3:description
Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
n3:dosage
n28:271B5BC3-363D-11E5-9242-09173F13E4C5 n28:271B5BC4-363D-11E5-9242-09173F13E4C5 n28:271B5BC5-363D-11E5-9242-09173F13E4C5 n28:271B5BC6-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Umapathy NS, Ganapathy V, Ganapathy ME: Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004 Jul;21(7):1303-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15290873
n3:group
investigational approved
n3:halfLife
Approximately 4.08 hours. Increased in patients with renal function impairment.
n3:indication
Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.
owl:sameAs
n22:DB01610 n24:DB01610
dcterms:title
Valganciclovir
adms:identifier
n9:DB01610 n10:57721 n11:64147 n12:46505524 n13:0004-0038-22 n14:PA10227 n20:Valganciclovir
n3:mechanismOfAction
Valganciclovir is a prodrug of ganciclovir that exists as a mixture of two diastereomers. After administration, these diastereomers are rapidly converted to ganciclovir by hepatic and intestinal esterases. In cytomegalovirus (CMV)-infected cells, ganciclovir is initially phosphorylated to the monophosphate form by viral protein kinase, then it is further phosphorylated via cellular kinases to produce the triphosphate form. This triphosphate form is slowly metabolized intracellularly. The phosphorylation is dependent upon the viral kinase and occurs preferentially in virus-infected cells. The virustatic activity of ganciclovir is due to the inhibition of viral DNA synthesis by ganciclovir triphosphate. Ganciclovir triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand. Ganciclovir inhibits viral DNA polymerases more effectively than it does cellular polymerase, and chain elongation resumes when ganciclovir is removed.
n3:packager
n27:271B5BC0-363D-11E5-9242-09173F13E4C5 n27:271B5BBE-363D-11E5-9242-09173F13E4C5 n27:271B5BBF-363D-11E5-9242-09173F13E4C5
n3:patent
n23:2154721 n23:6083953
n3:routeOfElimination
The major route of elimination of valganciclovir is by renal excretion as ganciclovir through glomerular filtration and active tubular secretion.
n3:synonym
L-valine, ester with ganciclovir Valcyte Cymeval Valganciclovir
n3:toxicity
It is expected that an overdose of valganciclovir could also possibly result in increased renal toxicity.
n3:volumeOfDistribution
* 0.703 ± 0.134 L/kg
n3:proteinBinding
Plasma protein binding of ganciclovir is 1% to 2% over concentrations of 0.5 and 51 mg/mL.
n3:synthesisReference
Romi Singh, Vishnubhotla Nagaprasad, Nidhi Singh, "Processes for the Preparation of Solid Dosage Forms of Amorphous Valganciclovir Hydrochloride." U.S. Patent US20070292499, issued December 20, 2007.
n18:hasConcept
n19:M0334922
foaf:page
n16:valganciclovir.htm n17:val1584.shtml n26:valganciclovir.html
n3:IUPAC-Name
n4:271B5BCB-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5BD1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5BD0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5BCD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5BCE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5BCF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5BC9-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5BC7-363D-11E5-9242-09173F13E4C5 n4:271B5BCA-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5BC8-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:J05AB14
n3:H-Bond-Acceptor-Count
n4:271B5BD7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5BD8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5BD2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5BD3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5BD5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5BD4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5BD6-363D-11E5-9242-09173F13E4C5
n3:absorption
Valganciclovir is well absorbed from the gastrointestinal tract and the absolute bioavailability from valganciclovir tablets (following administration with food) is approximately 60%.
n3:affectedOrganism
Human Herpes Virus
n3:casRegistryNumber
175865-60-8
n3:category
n3:clearance
* 3.07+/- 0.64 mL/min/kg [IV administration] * 5.3 L/hr [Patient with creatinine clearance of 70.4 mL/min]
n3:containedIn
n25:271B5BC2-363D-11E5-9242-09173F13E4C5 n25:271B5BC1-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5BDD-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5BDF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5BE0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5BDC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5BDB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5BDE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5BCC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5BD9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5BDA-363D-11E5-9242-09173F13E4C5